Actively Recruiting
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-06
50
Participants Needed
1
Research Sites
388 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this prospective, single arm, open label, clinical trial, a total of 50 acute leukemia of ambiguous lineage patients will be enrolled. Patients will receive acute lymphoblastic leukemia (ALL) -based chemotherapy and are permitted to receive allogeneic hematopoietic stem cell transplantation (HSCT) after CR . Otherwise, they will finish the consolidation chemotherapy. Patients with t(9;22) will receive chemotherapy combined with tyrosine kinase inhibitors. The purpose of current study is to evaluate the clinical efficacy of ALL-based chemotherapy，effect of genetic abnormality and minimal residual disease (MRD) on prognosis in patients with acute leukemia of ambiguous lineage.
CONDITIONS
Official Title
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged above 14 years with acute leukemia of ambiguous lineage
- Eastern Cooperative Oncology Group (ECOG) Performance status 2
- Adequate organ function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); SGOT and SGPT ≤ 2.5 x ULN; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless tumor related
- Adequate cardiac function with ejection fraction ≥ 45% on MUGA scan
- Laboratory values at or above lower limit of normal (LLN) for potassium, magnesium, and phosphorus, or corrected to normal before first dose
- Signed informed consent form
You will not qualify if you...
- Impaired cardiac function: long QT syndrome or family history; resting bradycardia (<50 bpm); ejection fraction < 45% on MUGA; QTc interval > 450 msec on ECG after electrolyte correction
- Myocardial infarction within 12 months before study start
- Other significant heart diseases such as unstable angina, congestive heart failure, uncontrolled hypertension or arrhythmias
- Other severe or uncontrolled medical conditions including another primary malignant disease requiring treatment, acute or chronic liver, pancreatic or severe renal disease
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
HBDH
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
J
Jianxiang Wang, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here